Abstract
Antiepileptic drugs (AEDs) are the mainstay of treatment for 1% of the human population suffering from epilepsy.1 They are also increasingly used for several non-epileptic neurological conditions, such as trigeminal neuralgia, neuropathic pain syndromes, migraine and psychiatric disorders.2 Three percent of patients who receive AEDs experience adverse cutaneous drug reactions (ACDR),3 which can range across a wide spectrum from mild to moderate eruptions, such as maculopapular rash and, urticaria, to severe and life-threatening conditions, such as drug reactions with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).1,4-5
This article is protected by copyright. All rights reserved.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.